These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1012 related items for PubMed ID: 23277268

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
    Lee SI, Song DH, Shin DW, Kim JH, Lee YS, Hwang JW, Park TW, Yook KH, Lee JI, Bahn GH, Hirata Y, Goto T, Takita Y, Takahashi M, Lee S, Treuer T.
    Asia Pac Psychiatry; 2014 Dec; 6(4):386-96. PubMed ID: 25345739
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study.
    Adler L, Tanaka Y, Williams D, Trzepacz PT, Goto T, Allen AJ, Escobar R, Upadhyaya HP.
    J Clin Psychopharmacol; 2014 Aug; 34(4):461-6. PubMed ID: 24977716
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
    Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz PT, Williams DW, Kelsey D.
    J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
    [Abstract] [Full Text] [Related]

  • 9. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
    Adler LA, Sutton VK, Moore RJ, Dietrich AP, Reimherr FW, Sangal RB, Saylor KE, Secnik K, Kelsey DK, Allen AJ.
    J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
    [Abstract] [Full Text] [Related]

  • 10. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
    Simpson D, Plosker GL.
    Drugs; 2004 Dec; 64(2):205-22. PubMed ID: 14717619
    [Abstract] [Full Text] [Related]

  • 11. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
    Prasad S, Harpin V, Poole L, Zeitlin H, Jamdar S, Puvanendran K, SUNBEAM Study Group.
    Curr Med Res Opin; 2007 Feb; 23(2):379-94. PubMed ID: 17288692
    [Abstract] [Full Text] [Related]

  • 12. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.
    Walker DJ, Mason O, Clemow DB, Day KA.
    Postgrad Med; 2015 Feb; 127(7):686-701. PubMed ID: 26343377
    [Abstract] [Full Text] [Related]

  • 13. Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.
    Wehmeier PM, Schacht A, Ulberstad F, Lehmann M, Schneider-Fresenius C, Lehmkuhl G, Dittmann RW, Banaschewski T.
    J Clin Psychopharmacol; 2012 Oct; 32(5):653-60. PubMed ID: 22926599
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
    Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, García-Polavieja MJ, Gilaberte I, Escobar R.
    Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
    [Abstract] [Full Text] [Related]

  • 16. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.
    Adler LA, Spencer TJ, Williams DW, Moore RJ, Michelson D.
    J Atten Disord; 2008 Nov; 12(3):248-53. PubMed ID: 18448861
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD.
    Sobanski E, Sabljic D, Alm B, Baehr C, Dittmann RW, Skopp G, Strohbeck-Kuehner P.
    Pharmacopsychiatry; 2012 May; 45(3):100-7. PubMed ID: 22174029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.